V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330012830 | 330008982 | 1.08 | 53 | Palliative (P) | 2017-10-16 | 2018-01-01 | FCR Oral - Cycle 2 onwards | null | null | 330020602 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330012831 | 330005473 | null | 75.9 | Palliative (P) | 2017-04-20 | 2017-05-14 | BUSULFAN + MELPHALAN | null | N | 330020665 | BENDAMUSTINE |
| 330012832 | 330010881 | 1.57 | 63 | Palliative (P) | 2016-04-19 | 2016-04-19 | DACTINOMYCIN + CYCLO + VINCRISTINE | 2 | N | 330020977 | AML17 TRIAL |
| 330012833 | 330009008 | 1.7 | 80 | Curative (C) | 2015-06-25 | 2015-06-25 | Doxorubicin + Methotrexate | N | N | 330021007 | BLEOMYCIN + VINCRISTINE |
| 330012834 | 330005528 | 1.65 | 45.1 | Palliative (P) | 2014-07-16 | 2014-10-20 | MELPHALAN | N | N | 330021093 | EP |
| 330012836 | 330005539 | 1.77 | 64.5 | Palliative (P) | 2017-06-07 | 2017-09-09 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | null | 330021120 | CARBOPLATIN + CETUXIMAB + FU |
| 330012837 | 330005551 | 1.79 | 119.5 | Neo-adjuvant (N) | 2017-03-26 | 2017-03-26 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 330021284 | CAPECITABINE + STREPTOZOCIN |
| 330012838 | 330005555 | 1.72 | 80 | Curative (C) | null | 2016-05-22 | LENALIDOMIDE | N | N | 330021301 | BEP |
| 330012839 | 330005556 | 1.71 | 76.1 | Disease modification (D) | 2014-09-20 | 2014-09-20 | Pazopanib | 2 | N | 330021309 | TOPOTECAN |
| 330012840 | 330005566 | null | 68 | Curative (C) | 2015-08-28 | 2016-07-02 | PONATINIB | null | N | 330021342 | CVP |
| 330012841 | 330009043 | 1.6 | 63 | Curative (C) | 2015-03-06 | 2016-03-21 | EP/EMA | 2 | N | 330021428 | MITOTANE |
| 330012842 | 330005582 | 1.59 | 41.4 | Palliative (P) | 2016-11-22 | 2017-01-17 | PONATINIB | null | null | 330021497 | FLUOROURACIL |
| 330012843 | 330005593 | 1.86 | 82.9 | Palliative (P) | 2014-06-30 | 2014-07-01 | R Chlorambucil | 02 | null | 330021602 | DOCETAXEL + NINTEDANIB |
| 330012844 | 330005598 | null | 60.4 | Palliative (P) | 2016-07-10 | 2016-10-14 | Alemtuz+Fludara+Melphalan RIC MUD | null | null | 330021653 | IVA |
| 330012845 | 330005602 | 1.59 | 59 | Curative (C) | 2018-01-30 | 2018-01-31 | AML17 TRIAL | Y | N | 330021660 | DACTINOMYCIN |
| 330012846 | 330005613 | null | null | Curative (C) | 2014-09-03 | 2014-10-23 | Doxorubicin + Ifosfamide | N | N | 330021734 | EC |
| 330012847 | 330005629 | 1.82 | null | null | null | 2018-01-22 | CVP R | null | null | 330022010 | CVD |
| 330012848 | 330005637 | 1.5 | 22.9 | Neo-adjuvant (N) | null | 2019-09-05 | Clofarabine + Cytarabine | null | N | 330022152 | THALIDOMIDE |
| 330012849 | 330005643 | 1.71 | 71.7 | Curative (C) | 2018-01-07 | 2018-01-14 | Nilotinib | 02 | N | 330022242 | EMA |
| 330012850 | 330005650 | 1.65 | 51.9 | Palliative (P) | 2017-02-26 | 2017-02-27 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | N | 330022302 | ERLOTINIB |
| 330012851 | 330005676 | 1.83 | 23.7 | Adjuvant (A) | 2018-10-03 | 2018-10-10 | BOP | 01 | null | 330022813 | BEVACIZUMAB + TEMOZOLOMIDE |
| 330012852 | 330009104 | 1.76 | 99.5 | Palliative (P) | 2017-07-16 | 2017-07-18 | NCRN402 BEACON TRIAL | N | N | 330022926 | BEVACIZUMAB |
| 330012853 | 330013193 | 1.67 | 72 | Curative (C) | null | 2017-07-13 | Gemcitabine + Paclitaxel | null | N | 330022938 | GEMCITABINE |
| 330012855 | 330005704 | 1.71 | null | Palliative (P) | 2019-12-15 | 2019-12-15 | Bevacizumab | 02 | N | 330023021 | UKALL2014 |
| 330012856 | 330005722 | 1.56 | 11.3 | Palliative (P) | 2018-12-15 | 2019-01-26 | AML18 PILOT TRIAL | 02 | N | 330023242 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 330012857 | 330009127 | 1.64 | 63.2 | Palliative (P) | 2018-10-24 | 2018-12-26 | CAP | N | N | 330023279 | CAPECITABINE |
| 330012858 | 330005743 | 1.73 | 87 | Palliative (P) | 2019-01-31 | 2019-02-01 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | 330023355 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330012859 | 330005759 | null | 59 | Curative (C) | 2017-03-28 | 2017-08-01 | Capecitabine | 02 | N | 330023502 | FMD |
| 330012860 | 330005787 | 1.41 | 122 | Curative (C) | 2018-08-18 | 2018-08-18 | Cytarabine Low Dose | N | N | 330023758 | VDC |
| 330012861 | 330005790 | 1.71 | 64.1 | Curative (C) | 2015-10-09 | 2017-04-03 | VeIP | N | N | 330023791 | IFOSFAMIDE |
| 330012862 | 330005792 | 1.76 | 31 | null | null | 2015-06-25 | BORTEZOMIB + RITUXIMAB | N | N | 330023816 | UKALL 2011 |
| 330012863 | 330005804 | 1.32 | 76.8 | Not known (9) | null | 2016-09-08 | Carboplatin + Cetux + FU (>Cycle 2) | Y | N | 330023868 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330012864 | 330005809 | null | 64.5 | Neo-adjuvant (N) | 2018-08-14 | 2018-08-22 | AML 19 TRIAL | N | N | 330023886 | UKALL60+ |
| 330012865 | 330005821 | 1.57 | 67.9 | Adjuvant (A) | 2016-10-01 | 2016-10-01 | Cyclophosphamide PO +Vinorelbine IV | N | N | 330023962 | IFOSFAMIDE |
| 330012866 | 330005826 | null | 80.6 | Curative (C) | 2017-01-11 | 2017-07-03 | Mitotane 5.5 - 10g | N | N | 330024003 | FLUDARABINE + MELPHALAN |
| 330012867 | 330005833 | 1.88 | 101.2 | Palliative (P) | 2018-07-04 | 2018-07-04 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 330024076 | CLADRIBINE |
| 330012868 | 330009180 | 1.83 | 56.3 | Curative (C) | 2018-06-06 | 2018-08-23 | Carboplatin + Cetux + FU (Cycle 1) | null | null | 330024126 | HYDROXYCARBAMIDE |
| 330012869 | 330009184 | 1.79 | 74.6 | Disease modification (D) | 2017-07-15 | 2017-08-28 | VeIP | N | N | 330024179 | VIDE |
| 330012870 | 330010998 | 1.76 | 70 | Not known (9) | 2019-05-15 | 2019-10-02 | Clofarabine + Cytarabine + Idarubicin | N | N | 330024281 | NCRN402 BEACON TRIAL |
| 330012871 | 330005880 | 1.76 | 17.8 | Palliative (P) | 2016-08-19 | 2016-09-02 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | Y | N | 330024378 | VIDE |
| 330012872 | 330005883 | 1.61 | null | Palliative (P) | 2016-11-08 | 2017-09-22 | CISPLATIN + ETOPOSIDE + PACLITAXEL | 2 | Y | 330024385 | IMATINIB |
| 330012873 | 330005891 | null | 14 | Neo-adjuvant (N) | 2015-08-18 | 2015-08-18 | STS Rhabdomyosarcoma RMS 2005 IVA | N | null | 330024412 | IVA |
| 330012875 | 330005902 | 1.85 | 87.8 | Palliative (P) | 2016-12-22 | 2017-01-03 | BCG Intravesical | 02 | N | 330024492 | LIPOSOMAL DAUNORUBICIN |
| 330012876 | 330011008 | 1.69 | null | Curative (C) | 2015-04-22 | 2015-04-22 | Cladribine (subcut) 5 days | N | N | 330024541 | CVP |
| 330012877 | 330005922 | 1.8 | null | Neo-adjuvant (N) | 2015-01-12 | 2015-01-17 | CVP R | N | N | 330024608 | IFOSFAMIDE |
| 330012878 | 330005931 | 1.76 | 63.2 | Palliative (P) | 2017-07-09 | 2017-07-09 | MACE | N | N | 330024744 | LIPOSOMAL DAUNORUBICIN |
| 330012879 | 330005934 | 1.8 | 56.4 | Curative (C) | 2016-02-27 | 2016-03-04 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 330024769 | CARBO + THIOTEPA + TOPOTECAN |
| 330012880 | 330005945 | 1.77 | 87.8 | Palliative (P) | 2014-03-05 | 2014-03-05 | ALL UKALL2011 Maintenance A2 | N | N | 330024851 | CVD |
| 330012881 | 330005957 | null | 101.8 | Palliative (P) | 2016-05-21 | 2016-05-26 | CNS LGG Irinotecan & Bevacizumab | 02 | N | 330024888 | MERCAPTOPURINE |
| 330012882 | 330005973 | 1.49 | 119.5 | Curative (C) | null | 2018-11-03 | STS Rhabdomyosarcoma RMS 2005 IVA | null | N | 330025024 | LENVATINIB |